Imcivree Hypothalamic Obesity Data: Weight Loss Holds at 18.8% After Two Years
Two-year TRANSCEND data show Rhythm's Imcivree (setmelanotide) keeps an 18.8% BMI cut in acquired hypothalamic obesity, as AstraZeneca bid talk swirls.
Two-year TRANSCEND data show Rhythm's Imcivree (setmelanotide) keeps an 18.8% BMI cut in acquired hypothalamic obesity, as AstraZeneca bid talk swirls.